Evidence map›Paper›PMID 36869232›Full record

ArticleCancer immunology, immunotherapy : CII2023

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach.

Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Enrico Cortesi, Ernesto Rossi, Giovanni Schinzari, Giampaolo Tortora, Silverio Tomao, Giulia Fiscon, Lorenzo Farina and 14 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Andrea Botticelli *Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Alessio Cirillo *Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy. alessio.cirillo@uniroma1.it.
Giulia PomatiDepartment of Molecular Medicine, Sapienza University of Rome, Viale Regina Elena 291, 00161, Rome, Italy.
Enrico CortesiDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Ernesto RossiMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
Giovanni SchinzariMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
Giampaolo TortoraMedical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
Silverio TomaoDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Giulia FisconDepartment of Computer, Control, and Management Engineering "Antonio Ruberti", Sapienza University of Rome, Via Ariosto 25, 00185, Rome, Italy.
Lorenzo FarinaDepartment of Computer, Control, and Management Engineering "Antonio Ruberti", Sapienza University of Rome, Via Ariosto 25, 00185, Rome, Italy.
Simone ScagnoliDepartment of Medical and Surgical Sciences and Translational Medicine, University of Rome "Sapienza", 00185, Rome, Italy.
Simona PisegnaDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Fabio CiurluiniDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Antonella ChiavassaDepartment of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Sasan AmirhassankhaniGuy's and St Thomas' NHS Foundation Trust, Westminster Bridge Rd, Bishop's, London, SE1 7EH, UK.
Fulvia CeccarelliArthritis Center, Dipartimento Di Scienze Cliniche Internistiche, Anestesiologiche E Cardiovascolari, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Fabrizio ContiArthritis Center, Dipartimento Di Scienze Cliniche Internistiche, Anestesiologiche E Cardiovascolari, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
Alessandra Di FilippoLaboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, University of Rome "Sapienza", 00161, Rome, Italy.
Ilaria Grazia ZizzariLaboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, University of Rome "Sapienza", 00161, Rome, Italy.
Chiara NapoletanoLaboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, University of Rome "Sapienza", 00161, Rome, Italy.
Aurelia RughettiLaboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, University of Rome "Sapienza", 00161, Rome, Italy.
Marianna NutiLaboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, University of Rome "Sapienza", 00161, Rome, Italy.
Silvia Mezi *Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, 00185, Rome, Italy.
Paolo Marchetti *Istituto Dermopatico Dell'Immacolata, 00167, Rome, Italy.
Sapienza University of Rome · ITPoliclinico Umberto I · ITAgostino Gemelli University Polyclinic · ITGuy's and St Thomas' NHS Foundation Trust · GBIstituto Dermopatico dell'Immacolata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have particular, immune-related adverse events (irAEs), as a consequence of interfering with self-tolerance mechanisms. The incidence of irAEs varies depending on ICI class, administered dose and treatment schedule. The aim of this study was to define a baseline (T0) immune profile (IP) predictive of irAE development.

methodsA prospective, multicenter study evaluating the immune profile (IP) of 79 patients with advanced cancer and treated with anti-programmed cell death protein 1 (anti-PD-1) drugs as a first- or second-line setting was performed. The results were then correlated with irAEs onset. The IP was studied by means of multiplex assay, evaluating circulating concentration of 12 cytokines, 5 chemokines, 13 soluble immune checkpoints and 3 adhesion molecules. Indoleamine 2, 3-dioxygenase (IDO) activity was measured through a modified liquid chromatography-tandem mass spectrometry using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. A connectivity heatmap was obtained by calculating Spearman correlation coefficients. Two different networks of connectivity were constructed, based on the toxicity profile.

resultsToxicity was predominantly of low/moderate grade. High-grade irAEs were relatively rare, while cumulative toxicity was high (35%). Positive and statistically significant correlations between the cumulative toxicity and IP10 and IL8, sLAG3, sPD-L2, sHVEM, sCD137, sCD27 and sICAM-1 serum concentration were found. Moreover, patients who experienced irAEs had a markedly different connectivity pattern, characterized by disruption of most of the paired connections between cytokines, chemokines and connections of sCD137, sCD27 and sCD28, while sPDL-2 pair-wise connectivity values seemed to be intensified. Network connectivity analysis identified a total of 187 statistically significant interactions in patients without toxicity and a total of 126 statistically significant interactions in patients with toxicity. Ninety-eight interactions were common to both networks, while 29 were specifically observed in patients who experienced toxicity.

conclusionsA particular, common pattern of immune dysregulation was defined in patients developing irAEs. This immune serological profile, if confirmed in a larger patient population, could lead to the design of a personalized therapeutic strategy in order to prevent, monitor and treat irAEs at an early stage.

Indexed as

Antineoplastic Agents, ImmunologicalNeoplasmsCytokinesHumansProspective StudiesRetrospective StudiesTandem Mass SpectrometryAntineoplastic Agents, ImmunologicalCytokinesImmunotherapyNetworkSolid tumorsSoluble profileToxicity

Identifiers

PMID36869232
PMCPMC10264536
OpenAlexW4323039544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.